( March 3, 2025, 11:56 AM EST) -- SAN FRANCISCO — An April hearing will be held in a California federal court to consider a motion filed by two drug manufacturers to dismiss a complaint alleging that Oxbryta (voxelotor), a prescription medication used for the treatment of sickle cell disease (SCD), caused a man to experience an increased rate of vaso-occlusive crises (VOCs) and to suffer a stroke....